Birch Pollen Allergy – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Birch Pollen Allergy – Pipeline Review, H1 2017’, provides an overview of the Birch Pollen Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Birch Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Birch Pollen Allergy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy

The report reviews pipeline therapeutics for Birch Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Birch Pollen Allergy therapeutics and enlists all their major and minor projects

The report assesses Birch Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Birch Pollen Allergy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Birch Pollen Allergy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Birch Pollen Allergy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ALK-Abello A/S

Anergis SA

Biomay AG

Circassia Pharmaceuticals Plc

HAL Allergy BV

Laboratorios LETI SL

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Birch Pollen Allergy - Overview

Birch Pollen Allergy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Birch Pollen Allergy - Therapeutics Assessment

Assessment by Target

Assessment by Route of Administration

Assessment by Molecule Type

Birch Pollen Allergy - Companies Involved in Therapeutics Development

ALK-Abello A/S

Anergis SA

Biomay AG

Circassia Pharmaceuticals Plc

HAL Allergy BV

Laboratorios LETI SL

Birch Pollen Allergy - Drug Profiles

Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AllerT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BM-31 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Birch Pollen Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Birch Pollen Allergy - Dormant Projects

Birch Pollen Allergy - Discontinued Products

Birch Pollen Allergy - Product Development Milestones

Featured News & Press Releases

Feb 08, 2017: Anergis Completes Patient Recruitment In Large-Scale ATIBAR Trial With Ultra-Fast Allergy Immunotherapy AllerT

Jun 07, 2016: Anergis to Present New Data on Lead Compound AllerT at the 35th European Academy of Allergy and Clinical Immunology Congress 2016

May 17, 2016: HAL Allergy has successfully completed its Phase III short-term efficacy trial with its sublingual allergen immunotherapy (SLIT) liquid product for the treatment of birch pollen allergy

Jun 04, 2015: Anergis to Present Three Scientific Posters at 34th European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015

Apr 01, 2015: Anergis Announces Completion of Treatment in AllerT Phase II Dose-Ranging Trial

Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study Results in an Approved, Accelerated up-dosing Regimen

Feb 23, 2015: Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting

Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT

Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT

May 27, 2014: Anergis to Present New COP Allergy Vaccine Data at EAACI Conference 2014 in Copenhagen

Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT

Feb 27, 2014: Phase IIb Results of Anergis´ Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego

Oct 21, 2013: Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis's Birch Pollen Allergy Vaccine AllerT

Sep 10, 2013: Anergis Reports Positive Phase IIb Data for Birch Pollen Allergy Vaccine AllerT

Jan 23, 2013: Anergis Obtains US Patent For Lead Product AllerT

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Birch Pollen Allergy, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Birch Pollen Allergy – Pipeline by ALK-Abello A/S, H1 2017

Birch Pollen Allergy – Pipeline by Anergis SA, H1 2017

Birch Pollen Allergy – Pipeline by Biomay AG, H1 2017

Birch Pollen Allergy – Pipeline by Circassia Pharmaceuticals Plc, H1 2017

Birch Pollen Allergy – Pipeline by HAL Allergy BV, H1 2017

Birch Pollen Allergy – Pipeline by Laboratorios LETI SL, H1 2017

Birch Pollen Allergy – Dormant Projects, H1 2017

Birch Pollen Allergy – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Birch Pollen Allergy, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports